Caris Life Sciences, Inc.
CAI
$24.03
-$0.79-3.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 85.37% | 100.51% | 96.97% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 85.37% | 100.51% | 96.97% | -- | -- |
| Cost of Revenue | 21.12% | 16.94% | 16.89% | -- | -- |
| Gross Profit | 140.42% | 195.83% | 199.86% | -- | -- |
| SG&A Expenses | 17.17% | 22.49% | 21.57% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.18% | 18.30% | 14.57% | -- | -- |
| Operating Income | 188.17% | 148.62% | 117.55% | -- | -- |
| Income Before Tax | 137.64% | 112.38% | 75.85% | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 137.68% | 112.43% | 75.85% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 137.68% | 112.43% | 75.85% | -- | -- |
| EBIT | 188.17% | 148.62% | 117.55% | -- | -- |
| EBITDA | 223.62% | 169.87% | 132.53% | -- | -- |
| EPS Basic | 102.35% | 27.24% | -4.60% | -- | -- |
| Normalized Basic EPS | 107.05% | 94.17% | 58.18% | -- | -- |
| EPS Diluted | 102.23% | 27.09% | -4.72% | -- | -- |
| Normalized Diluted EPS | 106.77% | 93.93% | 57.95% | -- | -- |
| Average Basic Shares Outstanding | 557.44% | 540.77% | 368.25% | -- | -- |
| Average Diluted Shares Outstanding | 574.30% | 561.14% | 388.67% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |